HeyJaredMark F. Witcher
- Indexed articles, last 90 days
- 4
- Latest publication
- Aug 18, 2026
- Outlet visibility, for Pharmaceuticalonline
- Top 5M sites
- Earliest in this view
- Jul 8, 2026
Latest articles
A Much-Improved Approach For Understanding And Managing Safety Risks (opens the original)
Read excerpt
By Mark F. Witcher, Ph.D., biopharma operations subject matter expert Safety is an essential part of every enterprise, including the pharmaceutical and medical device industries. This article describes how causal mechanism and effect analysis (CMEA)1 and its principles can be used to develop and maintain safer working environments. CMEA provides two complementary analysis methods for keeping everyone safe. The first resembles the classical Swiss cheese model of control barriers blocking threats
A Much-Improved Approach For Understanding And Managing Safety Risks (opens the original)
Read excerpt
By Mark F. Witcher, Ph.D., biopharma operations subject matter expert Safety is an essential part of every enterprise, including the pharmaceutical and medical device industries. This article describes how causal mechanism and effect analysis (CMEA)1 and its principles can be used to develop and maintain safer working environments. CMEA provides two complementary analysis methods for keeping everyone safe. The first resembles the classical Swiss cheese model of control barriers blocking threats
Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis (opens the original)
Read excerpt
By Mark F. Witcher, Ph.D., biopharma operations subject matter expert CDMOs are a vital part of the pharmaceutical and medical device industries. Building, executing, and maintaining an effective sponsor/CDMO working relationship is critical to developing, commercializing, and manufacturing many important therapies and products. This article explains how causal mechanism and effect analysis (CMEA)1 can be used to identify, analyze, and manage risks associated with using CDMOs. Since every sponso
Analyzing And Managing CDMO Project Risks Using Causal Mechanism & Effect Analysis (opens the original)
Read excerpt
By Mark F. Witcher, Ph.D., biopharma operations subject matter expert CDMOs are a vital part of the pharmaceutical and medical device industries. Building, executing, and maintaining an effective sponsor/CDMO working relationship is critical to developing, commercializing, and manufacturing many important therapies and products. This article explains how causal mechanism and effect analysis (CMEA)1 can be used to identify, analyze, and manage risks associated with using CDMOs. Since every sponso
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 5M sites
For Pharmaceuticalonline, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.